Last edition
News about "Chronic Idiopathic Urticaria "
Kashiv Biosciences, MS Pharma Partner to Commercialise Xolair Biosimilar in MENA Region
Kashiv BioSciences and MS Pharma have entered into an exclusive licensing and supply agreement for the commercialization of ADL-018, Kashiv’s biosimilar candidate to XOLAIR (bOmalizumab) in the Middle East and North Africa (MENA) region.
Chronic Idiopathic Urticaria | 07/08/2025 | By Dineshwori | 131
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members